Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777816 | 0.81 | TBXAS1 (1.00) | TBXAS1LMNAKMT2AMEN1LTA4H | |
| SCHEMBL10193662 | 0.81 | TBXAS1 (0.68) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL304568 | 0.80 | TBXAS1 (0.67) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL304566 | 0.80 | TBXAS1 (0.67) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3784432 | 0.78 | TBXAS1 (0.78) | TBXAS1LMNAKMT2AMEN1LTA4H | |
| SCHEMBL800614 | 0.77 | LTA4H (0.44) | LTA4H | |
| SCHEMBL305613 | 0.76 | TBXAS1 (0.67) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL800499 | 0.75 | TBXAS1 (0.62) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL305614 | 0.75 | TBXAS1 (0.62) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15751202 | 0.75 | TBXAS1 (0.62) | TBXAS1LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | TBXAS1 3557/4885LMNA 1246/4885SMN1; SMN2 2666/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | TBXAS1 4297/4885LMNA 1395/4885SMN1; SMN2 2525/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | TBXAS1 3289/4885LMNA 1157/4885SMN1; SMN2 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.